First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in United States. Its products includes ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs). First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was founded in 2019 and is based in San Diego, California.
Frequently asked questions
What sector does First Tracks Biotherapeutics (TRAX) operate in?
First Tracks Biotherapeutics belongs to the Healthcare sector and operates in the Biotechnology industry.
What is First Tracks Biotherapeutics (TRAX) current stock price?
As of the latest data, First Tracks Biotherapeutics stock price is $43.48, with a previous close of $44.05. First Tracks Biotherapeutics lost -$0.57 in the last trading session, representing a -1.29% loss.
What is First Tracks Biotherapeutics (TRAX) current market capitalization?
First Tracks Biotherapeutics market cap is approximately 1.55 billion.
What is First Tracks Biotherapeutics (TRAX) Earnings Per Share (EPS)?
The trailing EPS is -$4.52, and the forward EPS is -$3.66.
What is First Tracks Biotherapeutics (TRAX) EBITDA?
First Tracks Biotherapeutics EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -34.73 million.
Does First Tracks Biotherapeutics (TRAX) pay dividends?
No. First Tracks Biotherapeutics does not pay a dividend.
What is First Tracks Biotherapeutics (TRAX) beta (volatility) score?
First Tracks Biotherapeutics has a beta of 0.286, indicating lower volatility than the overall market.
